IL255010B2 - Methods of increasing strength and functionality with gdf8 inhibitors - Google Patents

Methods of increasing strength and functionality with gdf8 inhibitors

Info

Publication number
IL255010B2
IL255010B2 IL255010A IL25501017A IL255010B2 IL 255010 B2 IL255010 B2 IL 255010B2 IL 255010 A IL255010 A IL 255010A IL 25501017 A IL25501017 A IL 25501017A IL 255010 B2 IL255010 B2 IL 255010B2
Authority
IL
Israel
Prior art keywords
seq
antibody
composition
gdf8
placebo
Prior art date
Application number
IL255010A
Other languages
English (en)
Hebrew (he)
Other versions
IL255010A0 (en
IL255010B1 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL255010A0 publication Critical patent/IL255010A0/en
Publication of IL255010B1 publication Critical patent/IL255010B1/en
Publication of IL255010B2 publication Critical patent/IL255010B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL255010A 2015-04-15 2016-04-15 Methods of increasing strength and functionality with gdf8 inhibitors IL255010B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562147853P 2015-04-15 2015-04-15
US201562234899P 2015-09-30 2015-09-30
US201562261528P 2015-12-01 2015-12-01
PCT/US2016/027774 WO2016168613A1 (en) 2015-04-15 2016-04-15 Methods of increasing strength and functionality with gdf8 inhibitors

Publications (3)

Publication Number Publication Date
IL255010A0 IL255010A0 (en) 2017-12-31
IL255010B1 IL255010B1 (en) 2023-09-01
IL255010B2 true IL255010B2 (en) 2024-01-01

Family

ID=55809250

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255010A IL255010B2 (en) 2015-04-15 2016-04-15 Methods of increasing strength and functionality with gdf8 inhibitors

Country Status (14)

Country Link
US (3) US10934349B2 (OSRAM)
EP (1) EP3283519A1 (OSRAM)
JP (1) JP6877357B2 (OSRAM)
KR (2) KR20240128136A (OSRAM)
CN (1) CN107771081A (OSRAM)
AU (1) AU2016249015B2 (OSRAM)
CA (1) CA2982810A1 (OSRAM)
EA (1) EA201792298A1 (OSRAM)
HK (1) HK1250236A1 (OSRAM)
IL (1) IL255010B2 (OSRAM)
MA (1) MA49661A (OSRAM)
MX (1) MX2017013267A (OSRAM)
WO (1) WO2016168613A1 (OSRAM)
ZA (1) ZA201707550B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
KR102271635B1 (ko) * 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
AU2019226551B2 (en) * 2018-03-01 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
CA3094400A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
MX2021007394A (es) * 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
US20230390296A1 (en) 2020-10-30 2023-12-07 Keio University Novel treatment and prevention of sarcopenia-related diseases
US20250161255A1 (en) 2022-01-25 2025-05-22 Motoshi Hayano New therapy and prevention for suppressing aging-related disorders including sarcopenia
TW202430247A (zh) 2022-12-22 2024-08-01 美商供石公司 肌肉生長抑制素活化之選擇性及強效抑制劑

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor
WO2007047112A2 (en) * 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies
WO2010070094A1 (en) * 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011150008A1 (en) * 2010-05-26 2011-12-01 Regeneron Pharmaceuticals, Inc. Antibodies to human gdf8
US20130336982A1 (en) * 2012-06-15 2013-12-19 Pfizer Inc. Antagonist antibodies against gdf-8 and uses therefor

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1910220A (en) * 1931-10-21 1933-05-23 Kremser Alois Mechanically operated gate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
MXPA01013232A (es) 1999-07-20 2005-05-24 Pharmexa As Metodo para identificar la actividad de gdf-8.
US6670140B2 (en) 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
AU2004312411B8 (en) 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP1773041A1 (en) 2005-07-21 2007-04-11 Chao-Hung Wu Audio/video data transmission system using the internet to interconnect telephones
EP3327033A1 (en) 2005-08-19 2018-05-30 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2006321906C1 (en) 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008016314A1 (en) 2006-08-03 2008-02-07 Orico Limited Myostatin antagonists
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP5555635B2 (ja) 2007-11-05 2014-07-23 ノバルティス アーゲー 高脂血症または動脈硬化症などの疾患の処置に有用なｃｅｔｐ阻害剤としての４−ベンジルアミノ−１−カルボキシアシル−ピペリジン誘導体
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
KR20140005864A (ko) 2010-08-16 2014-01-15 암젠 인코퍼레이티드 미오스타틴에 결합하는 항체, 조성물 및 방법
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
AU2014307589A1 (en) * 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
AU2019226551B2 (en) 2018-03-01 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor
WO2007047112A2 (en) * 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies
WO2010070094A1 (en) * 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011150008A1 (en) * 2010-05-26 2011-12-01 Regeneron Pharmaceuticals, Inc. Antibodies to human gdf8
US20130336982A1 (en) * 2012-06-15 2013-12-19 Pfizer Inc. Antagonist antibodies against gdf-8 and uses therefor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOULD, DOUGLAS W., ET AL., CANCER CACHEXIA PREVENTION VIA PHYSICAL EXERCISE: MOLECULAR MECHANISMS., 1 June 2013 (2013-06-01) *
LEBRASSEUR, NATHAN K., ET AL., MYOSTATIN INHIBITION ENHANCES THE EFFECTS OF EXERCISE ON PERFORMANCE AND METABOLIC OUTCOMES IN AGED MICE., 1 September 2009 (2009-09-01) *
PADHI, DESMOND, ET AL., PHARMACOLOGICAL INHIBITION OF MYOSTATIN AND CHANGES IN LEAN BODY MASS AND LOWER EXTREMITY MUSCLE SIZE IN PATIENTS RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER., 1 October 2014 (2014-10-01) *
SHARP, MATTHEW, ET AL., THE EFFECTS OF A MYOSTATIN INHIBITOR ON LEAN BODY MASS, STRENGTH, AND POWER IN RESISTANCE TRAINED MALES., 1 December 2014 (2014-12-01) *
WAGNER, KATHRYN R., ET AL., A PHASE I/IITRIAL OF MYO-029 IN ADULT SUBJECTS WITH MUSCULAR DYSTROPHY., 1 May 2008 (2008-05-01) *

Also Published As

Publication number Publication date
US12029788B2 (en) 2024-07-09
MX2017013267A (es) 2018-08-15
US20240390489A1 (en) 2024-11-28
AU2016249015A1 (en) 2017-11-09
JP6877357B2 (ja) 2021-05-26
MA49661A (fr) 2020-06-03
IL255010A0 (en) 2017-12-31
ZA201707550B (en) 2018-11-28
US20210246198A1 (en) 2021-08-12
CN107771081A (zh) 2018-03-06
JP2018512435A (ja) 2018-05-17
US10934349B2 (en) 2021-03-02
CA2982810A1 (en) 2016-10-20
HK1250236A1 (zh) 2018-12-07
US20160304595A1 (en) 2016-10-20
KR20240128136A (ko) 2024-08-23
EA201792298A1 (ru) 2018-04-30
WO2016168613A1 (en) 2016-10-20
EP3283519A1 (en) 2018-02-21
IL255010B1 (en) 2023-09-01
AU2016249015B2 (en) 2022-03-24
KR20170135967A (ko) 2017-12-08

Similar Documents

Publication Publication Date Title
US12029788B2 (en) Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody
JP2022141868A (ja) 心血管リスクを低減させる方法
RU2567805C2 (ru) Антитела против gdf8 человека
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US8980268B2 (en) Methods for treating cancer by administering an anti-Ang-2 antibody
KR102482375B1 (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
KR20160115939A (ko) 중등-용량 스타틴 치료법에 의해 적당하게 조절되지 않는 고콜레스테롤혈증이 있는 환자의 치료 방법
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
IL266426A (en) Proteins bind to an antibody that opposes a leptin receptor
EP3661553A2 (en) Methods and compositions for treatment of amyloid deposition diseases
IL298099A (en) Anti-glp1r antagonist antibodies and methods of use thereof
JP2021515003A (ja) 体組成を変更するための方法
IL295979A (en) Anti-cd36 antibodies and their use for cancer treatment
IL296043A (en) Anti-gitro antibodies and their uses
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
EA040534B1 (ru) Способы увеличения безжировой массы тела с помощью антитела к gdf8 или его антигенсвязывающего фрагмента и тренировок с сопротивлением
CN115066272A (zh) Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
EA046653B1 (ru) Способы изменения состава тела
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis